Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
182,917,028
-
Total 13F shares
-
29,498,551
-
Share change
-
-1,806,175
-
Total reported value
-
$236,424,963
-
Put/Call ratio
-
74%
-
Price per share
-
$8.01
-
Number of holders
-
87
-
Value change
-
-$44,351,424
-
Number of buys
-
42
-
Number of sells
-
44
Institutional Holders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) as of Q4 2019
As of 31 Dec 2019,
Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) was held by
87 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,498,551 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Redmile Group, LLC, WELLINGTON MANAGEMENT GROUP LLP, Bellevue Group AG, BlackRock Inc., RTW INVESTMENTS, LP, PRIMECAP MANAGEMENT CO/CA/, PRICE T ROWE ASSOCIATES INC /MD/, ArrowMark Colorado Holdings LLC, and JANUS HENDERSON GROUP PLC.
This page lists
87
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.